Fox Chase Cancer Center News

PHILADELPHIA (September 22, 2021)—Salarius Pharmaceuticals Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center. The research, to be carried out by the laboratory of Johnathan Whetstine, PhD, the institute’s director, will help identify new indications and potential biomarkers for Salarius’ lead drug candidate, seclidemstat.

PHILADELPHIA (September 21, 2021)—Jeffrey M. Farma, MD, FACS, chief of the Division of General Surgery at Fox Chase Cancer Center, was appointed as the state chair of the American College of Surgeons Commission on Cancer (CoC) Cancer Liaison Program.

PHILADELPHIA (September 20, 2021)—Fox Chase Cancer Center will hold its 22nd annual Paws for the Cause dog walk to benefit cancer research as an in-person event this year, along with a two-week virtual event. Both events are hosted by the Fox Chase Board of Associates.

PHILADELPHIA (September 20, 2021) – Fox Chase Cancer Center is pleased to announce the hiring of Teresa Y. Lee, MD, PhD, as an assistant professor. Lee will focus on sarcoma and head and neck cancer.

PHILADELPHIA (September 17, 2021)—Results from the phase 3 INVICTUS clinical trial show that the drug ripretinib, also known by its brand name Qinlock, provides clinically meaningful improvement in overall median survival for patients with gastrointestinal stromal tumor (GIST) when compared with placebo.

PHILADELPHIA (September 15, 2021)—Fox Chase Cancer Center’s Edna “Eti” Cukierman, PhD, co-director of the Marvin & Concetta Greenberg Pancreatic Cancer Institute, recently published a “Landmark” commentary in the journal Cancer Research that explored the impact of a key study.

PHILADELPHIA (September 13, 2021)—A recent study from Fox Chase Cancer Center has found that in patients treated with radical cystectomy—removal of the bladder—those with cT1 micropapillary bladder cancer had similar or worse oncological outcomes compared with patients with cT2 conventional urothelial carcinoma.

PHILADELPHIA (September 11, 2021)—In a recent study, Fox Chase Cancer Center researchers highlighted immediate cardiopulmonary risks associated with patients undergoing minimally invasive partial nephrectomy or prostatectomy for low-grade, low-stage disease. The study compared these risks with those associated with disease surveillance.